NCT06836973

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Efficacy and Safety of Blinatumomab for Treatment of Refractory Myasthenia Gravis.

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 2 (estimated)
• Sponsor: Da, Yuwei, M.D. · Individual
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are: * Does Blinatumomab improve patients' clinical symptoms? * Is Blinatumomab safe for the treatment of myasthenia gravis? Participants will: * Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles. * Visit the clinic once every 4 weeks for checkups and tests. * Keep a diary of their symptoms and the types and dosages of medications.

Conditions

• Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	Blinatumomab	Blinatumomab is used at its starting dose of 9 µg per day and administered as continuous infusion for 5 days (total dose of 38.5 µg). After a 1-week pause, the patients receive a second 5-day infusion with blinatumomab of total 38.5 µg of the drug.

Timeline

• Start date: 2025-04-01
• Primary completion: 2028-03-31
• Completion: 2028-06-30
• First posted: 2025-02-20
• Last updated: 2025-03-25